Cart (0 Items)
Your cart is currently empty.
View Products
ProteoGenix offers an extensive portfolio of chemical and enzymatic conjugation solutions. We help you select the optimal strategy based on key criteria such as:
Whether you’re validating a concept or preparing for clinical phases, our experts and versatile conjugation toolbox ensure the most suitable solution for your program.
Our platform supports all antibody formats, from VHHs to IgGs, including Fabs, scFvs, and bispecific antibodies.
Our chemical and enzymatic conjugation technologies are designed to deliver >90% DAR homogeneity at the ratio you specify.
This tight DAR control, and its distribution, is essential for reducing ADC toxicity and avoiding the site-barrier effect.
Choose from a wide panel of cleavable and non-cleavable linkers, with expert guidance to ensure:
We also offer an extensive selection of payloads to tailor the optimal DAR/linker/payload configuration for your therapeutic objective.
We provide a full analytical suite, including: DAR, DAR distribution, drug location, % free drug, and all standard antibody QC measurements.
From antibody generation to conjugation, we support every step. This integrated approach lets us also fine-tune antibody affinity and kinetics, two critical factors that directly impact your ADC’s therapeutic success.